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Abstract
Anthracyclines  have  a  central  role  in  the
management  of  non-Hodgkin’s  lymphoma
(NHL).  The  cyclophosphamide,  doxorubicin,
vincristine, and prednisone (CHOP) treatment
regimen  has  been  the  standard  of  care  for
more  than  20  years.  Further  improvements
have  been  made  to  the  efficacy  of  this
chemotherapy by reducing the dosing interval
and adding rituximab to the regimen. A major
limitation to the use of anthracyclines is the
development of cardiotoxicity as a late adverse
event. Strategies to reduce cardiac events in-
clude changes to the dosing schedule for dox-
orubicin,  use  of  the  chelating  agent  dexra-
zoxane and the use of liposome-encapsulated
doxorubicin. This latter strategy has demon-
strated good efficacy and reduced cardiotoxi-
city in patients with NHL, including those at
risk of developing cardiac effects. 
Introduction
Since their introduction in the 1960s, the an-
thracyclines have gained a central role in the
treatment of non-Hodgkin’s lymphoma (NHL).
In  particular,  the  use  of  doxorubicin  in  the
standard  rituximab,  cyclophosphamide,  dox-
orubicin,  vincristine,  and  prednisone  (R-
CHOP) regimen means that a large proportion
of patients with aggressive lymphomas receive
anthracycline therapy. In this paper, a brief his-
tory of the development of anthracyclines, their
use in NHL, and the management of anthracy-
cline-related cardiotoxicity are presented. 
Development of anthracyclines 
The potential of anthracyclines was first rec-
ognized in 1960, when Federico Arcamone and
co-workers filed a patent application for the
“fermentative production and recovery of an
antibiotic obtained from Streptomyces kresto-
myceticus”.  In  1963,  a  novel  cytotoxic  com-
pound derived from S. peuceticus was isolated
simultaneously  by  researchers  in  Italy  and
France. The Italian group gave the compound
the  name  daunomycin,  the  French  group
named it rubidomycine. Elements from both
names were then combined to give the com-
pound the name daunorubicin. A hydroxylated
derivative of daunorubicin was subsequently
isolated by the Italian group and called adri-
amycin. It was later renamed doxorubicin to
conform  to  the  established  naming  conven-
tion. In preclinical studies, this new antitumor
antibiotic was shown to have greater activity
against solid murine tumors and a higher ther-
apeutic index than daunorubicin.1,2 Early clin-
ical  evaluation  of  doxorubicin  demonstrated
its efficacy in both adults and children with
acute and chronic leukemias.2
The first key demonstration of the efficacy
of CHOP in lymphoma was published in 1984.
Armitage and co-workers reported the results
of a clinical trial in 75 patients treated with
CHOP for diffuse histiocytic lymphoma; 51%
achieved  complete  remission  and  23  of  the
complete responders were alive and in com-
plete remission at a median of 38 months after
stopping  treatment.3 Ten  years  later,  the
Southwest  Oncology  Group  and  the  Eastern
Cooperative Oncology Group published the re-
sults of a prospective Phase III trial comparing
chemotherapy  regimens  commonly  used  at
that time to treat advanced NHL.4 CHOP was
therefore  compared  with  MACOP-B  (metho  -
trexate  with  leucovorin  rescue,  doxorubicin,
cyclophosphamide,  vincristine,  prednisone,
and  bleomycin),  ProMACE-CytaBOM  (pred-
nisone, doxorubicin, cyclophosphamide, etopo-
side,  followed  by  cytarabine,  bleomycin,  vin-
cristine,  methotrexate  with  leucovorin
rescue),  and  m-BACOD  (methotrexate  with
leucovorin rescue, bleomycin, doxorubicin, cy-
clophosphamide, vincristine, and dexametha-
sone) in 1138 patients (899 eligible for efficacy
analysis).  There  were  no  significant  differ-
ences in the efficacy of these regimens, but
CHOP  was  associated  with  improved  safety
and tolerability compared with the other regi-
mens (Figure 1). The authors therefore con-
cluded that CHOP remains the best available
treatment for patients with advanced-stage in-
termediate-grade or high-grade NHL.4The effi-
cacy of CHOP in the standard 21-day treatment
cycle could be further improved by the use of a
14-day treatment cycle with granulocyte-colony
stimulating  factor  (G-CSF)  support  in  both
young and elderly patients.5,6 Subsequently, it
was found that the addition of rituximab to the
CHOP regimen further increased its efficacy,7-10
and that six cycles of R-CHOP plus two addi-
tional cycles of rituximab were as effective as
eight cycles of R-CHOP.11
History of anthracycline-related
cardiotoxicity
Early studies of doxorubicin did not identify
cardiotoxicity as an adverse event. Although the
Phase I and II studies did demonstrate electro-
cardiographic changes in more than half of 97
patients who were prospectively studied, these
abnormalities  were  subclinical,  no  symptoms
were  mentioned,  and  additional  research  did
not suggest any cumulative cardiac toxicity of
doxorubicin.12 However,  10  years  after  these
first studies, cardiotoxicity started to be identi-
fied as a late side-effect of cumulative doses of
anthracyclines. An early analysis of this problem
demonstrated a correlation between the cumu-
lative dose of doxorubicin and the probability of
developing  congestive  heart  failure  (CHF)
(Figure  2).13 Subsequent  studies  confirmed
that the incidence of CHF increased from 3% at
a cumulative doxorubicin dose of 400 mg/m2 to
18% at a cumulative dose of 700 mg/m2.14 More-
over, CHF was often irreversible. Risk factors for
cardiotoxicity  included:  previous  exposure  to
anthracyclines, patient age, and a history of car-
diovascular  disease.14 Cardiotoxicity  is  also
seen with newer anthracyclines, such as epiru-
bicin.15 It is the main factor limiting anthracy-
cline use, and can result in discontinuation or
non-use of treatment for patients who might
otherwise benefit from this therapy.
Managing anthracycline 
cardiotoxicity
Treatment strategies designed to reduce an-
thracycline cardiotoxicity have included modi-
fication of the dosing regimen, treatment with
cardioprotective agents, and the use of lipo-
some-encapsulated forms of doxorubicin. 
Dose and schedule modification 
As higher cumulative doses of doxorubicin
are associated with a greater risk of CHF, then
maintaining doses below a maximum cumula-
tive dose may reduce patients’ risks.16 Never-
theless, such maximum doses cannot be used
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diac dysfunction has been seen in patients re-
ceiving lower than maximal doses, and some
patients are more susceptible to cardiotoxicity
than others.13,16Changes to the administration
of the anthracycline can also alter its toxicity.
Thus, long drug infusions instead of a single
injection  have  been  shown  to  be  less  car-
diotoxic.17,18 However, this approach is more
laborious than conventional treatment, partic-
ularly when doxorubicin is used in combina-
tion with other agents.
Use of dexrazoxane
Several studies have investigated the use of
dexrazoxane,  an  iron-chelating  agent  that
scavenges free radicals, as a means of limiting
anthracycline-related  cardiotoxicity.  Initially,
there were concerns that this agent might ad-
versely affect the antitumor activity of doxoru-
bicin.19 However, a subsequent systematic re-
view  of  nine  randomized  trials  found  that
dexrazoxane  significantly  reduced  patients’
risk of developing CHF, without affecting the
efficacy of doxorubicin, in terms of response
rate  or  survival.  The  authors  therefore  con-
cluded that dexrazoxane treatment should be
considered  in  patients  at  high  risk  of  car-
diotoxicity.20
Use of liposome-encapsulated 
doxorubicin 
Two liposome-encapsulated forms of dox-
orubicin are currently available: pegylated li-
posomal doxorubicin and non-pegylated lipo-
somal  doxorubicin  (NPLD).  Liposomes  are
microscopic structures consisting of one or
more concentric lipid bilayers, which encap-
sulate the active substance. These lipid struc-
tures  cannot  escape  the  vascular  space  in
areas that have tight capillary junctions, such
as the heart muscle, but can reach other tis-
sues. Thus, the pharmacokinetics and tissue
distribution of the active molecule are modi-
fied. In particular, NPLD is preferentially de-
livered to the liver, spleen, bone marrow, and
lymph nodes, compared with relatively little
entry  to  cardiac  muscle  and  the  gastroin-
testinal mucosa.21 This treatment may there-
fore reduce the cardiac toxicity of doxorubicin
while maintaining its antitumor efficacy. 
In patients with newly diagnosed aggres-
sive NHL, substitution of NPLD into the CHOP
regimen, to give COMP, produced a complete
response rate of 67.4%.22 Importantly, the use
of COMP in patients at risk of cardiotoxicity
has also produced promising results. A retro-
spective  analysis  of  rituximab-COMP  (R-
COMP) treatment for patients who either had
concurrent cardiac diseases or had been pre-
treated  with  anthracyclines  demonstrated  a
complete response rate of 76%.23 Moreover,
only one patient included in this analysis de-
veloped  acute  grade  III  cardiotoxicity.  A
prospective international study of R-COMP in
elderly  patients  with  aggressive  lymphoma
gave a complete remission rate of 57%, and
patients  showed  no  signs  of  cardiotoxicity.
Left  ventricular  ejection  fraction  did  not
change  during  treatment,  and  the  R-COMP
regimen was not associated with any increase
in acute cardiac toxicity.24 A meta-analysis of
two  studies  comparing  free  and  liposomal
doxorubicin (in patients with breast cancer,
not NHL) showed a significantly lower rate of
both  clinical  heart  failure,  and  clinical  and
subclinical  heart  failure  combined,  in  pa-
tients  treated  with  liposome-encapsulated 
doxorubicin.15
Conclusions
Anthracyclines  continue  to  play  a  central
role in the treatment of NHL. Moreover, the in-
troduction  of  liposome-encapsulated  doxoru-
bicin may allow their use to be extended to pa-
tients at risk of cardiotoxicity who would ben-
efit from this treatment. A key challenge now
in NHL is to maximize treatment outcomes,
through  new  biological  approaches  such  as
gene  profiling,  and  through  optimal  use  of
therapies across the diverse spectrum of lym-
phomas. This challenge to clinicians was the
theme of an international workshop, Moving
forward with new data and approaches: a fresh
Figure  2.  Risk  of  developing
congestive  heart  failure  (CHF)
in  relation  to  the  cumulative
dose of doxorubicin.13 Reprint  -
ed with permission from Von Hoff
DD et al. Risk factors for dox-
orubicin-induced  congestive
heart  failure.  Ann  Intern  Med
1979; 91:710-17. 
Figure  1.  Overall  survival  of
patients  with  non-Hodgkin’s
lymphoma  receiving  three  dif-
ferent  treatment  regimens  (3-
year  estimates  of  survival).4
CHOP  –  cyclophosphamide,
doxorubicin,  vincristine,  pred-
nisone; m-BACOD – methotre  -
xate  with  leucovorin  rescue,
bleomycin,  doxorubicin,  cyclo  -
phosphamide,  vincristine,  and
dexamethasone;  ProMACE-
CytaBOM  –  prednisone,  dox-
orubicin,  cyclophosphamide,
etoposide,  followed  by  cytara-
bine,  bleomycin,  vincristine,
methotrexate  with  leucovorin
rescue; MACOP-B – methotrex-
ate with leucovorin rescue, doxo  -
rubicin, cyclophosphamide, vin  -
cristine,  prednisone,  and  bleo  -
mycin.  Reprinted  with  permis-
sion  from  Fisher  RI  et  al.
Comparison of a standard regi-
men (CHOP) with three inten-
sive chemotherapy regimens for
advanced  non-Hodgkin’s  lym-
phoma. N Engl J Med 1993;328:
1002-6. ©Massachusetts Medical
Society. 
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look  at  anthracyclines  in  breast  cancer  and
NHL, which took place in Meldola, Italy, in Sep-
tember  2010.  This  meeting  reviewed  recent
data on the use of anthracyclines in the treat-
ment of breast cancer and NHL, with the aim of
providing guidance on how the management of
these diseases can be improved. The presenta-
tions on NHL at this meeting are summarized
in this supplement.
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